TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Instagram Outage Disrupts Thousands of U.S. Users 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Genetic testing company 23andMe Holding Co. (NASDAQ: ME) has filed for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the Eastern District of Missouri. The company announced the move on Monday, aiming to facilitate a court-supervised sale process while continuing operations.
The bankruptcy filing follows the rejection of a buyout offer from company co-founder Anne Wojcicki and her affiliates. Wojcicki has since stepped down as CEO but will stay on the board. Joe Selsavage has been appointed interim CEO to lead the company through the restructuring phase.
Facing mounting financial pressure and legal issues tied to a 2023 cybersecurity breach, 23andMe cited the Chapter 11 process as a necessary step to stabilize the business, reduce costs, and resolve outstanding liabilities. As part of the filing, the company secured $35 million in debtor-in-possession financing from JMB Capital Partners to maintain operations throughout the proceedings.
Despite the bankruptcy, 23andMe emphasized that customer data privacy and protection will remain intact and are a top priority during any asset sale. The company plans to solicit bids over a 45-day period, with any final transaction requiring regulatory approval.
Once a pioneer in at-home DNA testing, 23andMe has struggled with declining revenues, rising costs, and reputational damage following last year’s cyber incident. The firm is now seeking a buyer to preserve its core assets and continue its mission of delivering personalized genetic health insights.
This latest development marks a turning point for the once high-flying biotech firm, underscoring broader challenges in the consumer healthtech sector. Investors and customers alike will be closely watching as the company navigates its next chapter under bankruptcy protection.
